Joachim C Mertens
Overview
Explore the profile of Joachim C Mertens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
3291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hildenbrand F, Illi B, von Felten S, Bachofner J, Gawinecka J, von Eckardstein A, et al.
BMC Gastroenterol
. 2024 Jan;
24(1):54.
PMID: 38291388
Background & Aims: With the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced...
2.
Mertens J, Blanc-Guillemaud V, Claesen K, Cardona P, Hendriks D, Tyl B, et al.
Transl Stroke Res
. 2021 Nov;
13(6):959-969.
PMID: 34796454
The antifibrinolytic enzyme carboxypeptidase U (CPU, TAFIa, CPB2) is an appealing target for the treatment of acute ischemic stroke (AIS). Increased insights in CPU activation and inactivation during thrombolysis (rtPA)...
3.
Claesen K, Roth L, Mertens J, Hermans K, Sim Y, Hendriks D
Pharmaceutics
. 2021 Oct;
13(10).
PMID: 34684024
Statins (hydroxymethyl-glutaryl-CoA-reductase inhibitors) lower procarboxypeptidase U (proCPU, TAFI, proCPB2). However, it is challenging to prove whether this is a lipid or non-lipid-related pleiotropic effect, since statin treatment decreases cholesterol levels...
4.
Scheiner B, Pomej K, Kirstein M, Hucke F, Finkelmeier F, Waidmann O, et al.
J Hepatol
. 2021 Oct;
76(2):353-363.
PMID: 34648895
Background & Aims: Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival...
5.
Karbeyaz F, Kissling S, Jaklin P, Bachofner J, Brunner B, Mullhaupt B, et al.
J Hepatocell Carcinoma
. 2021 Jun;
8:565-574.
PMID: 34150679
Background: Direct-acting antivirals (DAA) have revolutionized the therapy of chronic hepatitis C (CHC) and have replaced previous PEG-interferon/ribavirin (PEG-IFN/RBV) treatment. Patients with CHC and advanced liver disease are at increased...
6.
Claesen K, Mertens J, Basir S, De Belder S, Maes J, Bosmans J, et al.
Clin Ther
. 2021 Apr;
43(5):908-916.
PMID: 33910760
Purpose: Statins are commonly used in patients with hypercholesterolemia to lower their cholesterol levels and to reduce their cardiovascular risk. There is also considerable evidence that statins possess a range...
7.
Pfister D, Gonzalo Nunez N, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al.
Nature
. 2021 Mar;
592(7854):450-456.
PMID: 33762733
Hepatocellular carcinoma (HCC) can have viral or non-viral causes. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients...
8.
Ruiz F, Wyss A, Rossel J, Sulz M, Brand S, Moncsek A, et al.
Br J Pharmacol
. 2021 Jan;
178(16):3157-3175.
PMID: 33511653
No abstract available.
9.
Claesen K, Mertens J, Leenaerts D, Hendriks D
Int J Mol Sci
. 2021 Jan;
22(2).
PMID: 33477318
Procarboxypeptidase U (proCPU, TAFI, proCPB2) is a basic carboxypeptidase zymogen that is converted by thrombin(-thrombomodulin) or plasmin into the active carboxypeptidase U (CPU, TAFIa, CPB2), a potent attenuator of fibrinolysis....
10.
Mertens J, Boisseau W, Leenaerts D, Di Meglio L, Loyau S, Lambeir A, et al.
J Thromb Haemost
. 2020 Sep;
18(12):3325-3335.
PMID: 32869423
Background: Carboxypeptidase U (CPU, CPB2, TAFIa) is a potent attenuator of fibrinolysis. The inhibition of CPU is thus an interesting strategy for improving thrombolysis. Objectives: The time course of CPU...